Witnessing the stock’s movement on the chart, on Wednesday, Zevra Therapeutics Inc (NASDAQ: ZVRA) had a quiet start as it plunged -8.66% to $10.12, before settling in for the price of $11.08 at the close. Taking a more long-term approach, ZVRA posted a 52-week range of $6.19-$13.16.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 29.64%. Meanwhile, its Annual Earning per share during the time was 29.64%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 152.69%. This publicly-traded company’s shares outstanding now amounts to $56.14 million, simultaneously with a float of $55.65 million. The organization now has a market capitalization sitting at $568.09 million. At the time of writing, stock’s 50-day Moving Average stood at $9.50, while the 200-day Moving Average is $8.93.
Zevra Therapeutics Inc (ZVRA) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Zevra Therapeutics Inc’s current insider ownership accounts for 0.87%, in contrast to 64.79% institutional ownership. According to the most recent insider trade that took place on Oct 10 ’25, this organization’s President and CEO sold 19,500 shares at the rate of 10.82, making the entire transaction reach 210,908 in total value, affecting insider ownership by 222,016.
Zevra Therapeutics Inc (ZVRA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.0 per share during the current fiscal year.
Zevra Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 152.69% and is forecasted to reach 0.55 in the upcoming year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
Let’s observe the current performance indicators for Zevra Therapeutics Inc (ZVRA). It’s Quick Ratio in the last reported quarter now stands at 7.81. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9.16.
In the same vein, ZVRA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.05, a figure that is expected to reach -0.03 in the next quarter, and analysts are predicting that it will be 0.55 at the market close of one year from today.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Going through the that latest performance of [Zevra Therapeutics Inc, ZVRA]. Its last 5-days volume of 1.03 million indicated improvement to the volume of 1.02 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 27.89% While, its Average True Range was 41.85.
Raw Stochastic average of Zevra Therapeutics Inc (ZVRA) in the period of the previous 100 days is set at 49.33%, which indicates a major rise in contrast to 3.05% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.60 that was higher than 0.53 volatility it exhibited in the past 100-days period.
